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State of the art on oocyte cryopreservation in female cancer patients: a critical review of the literature. 
ABSTRACT 
During the last decades, important advances in therapeutic options have led to increased survival rates in 
cancer patients; however, cancer treatments are associated with several potential adverse effects including 
infertility in those diagnosed during their reproductive years. A proper discussion about fertility 
preservation options before the use of therapies with potential gonadotoxicity (i.e. oncofertility counseling) 
is standard of care and should be offered to all patients of childbearing age. Temporary ovarian suppression 
with LH-RH analogs, oocyte and embryo cryopreservation are standard strategies for fertility preservation 
in female cancer patients. Oocyte cryopreservation should be preferred to embryo cryopreservation when 
this latter is prohibited by law, avoided for ethical or religious issues and in single women refusing sperm 
donation. Despite the increasing use of this strategy, data are still lacking about the efficacy and safety of 
the procedure in female cancer patients, with most of the evidence on this regard deriving from infertile 
non-oncologic women. This article aims at critically review the available evidence about the success of 
oocyte cryopreservation in female cancer patients with the final goal to further improve the oncofertility 
counseling of these women. 
Highlights: 
- Physicians should discuss fertility preservation with women facing gonadotoxic therapies. Oocyte 
cryopreservation is a standard procedure for fertility preservation in female cancer patients. 
- Data about the efficacy of the procedure specifically in cancer patients are still lacking, however the 
reassuring efficacy and safety results in non-oncologic patients can be reasonably translated in the cancer 
setting. 
- More data about the outcome of thawing/warming cycles in cancer patients are needed. Up to date, a 
registry of pregnancies in this population does not exist. 
Keywords: 
Oncofertility, oocyte cryopreservation, gonadotoxic therapies, pregnancy after cancer 
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Background 
Among patients diagnosed with malignant cancers worldwide, 3% to 10% are under 40 years of age.  
Cancer in reproductive age is twice as frequent in females than in males [1, 2]. Important advances in 
cancer treatments have led to increased survival rates over the past years; conversely these therapies 
expose patients to potential long term adverse effects, including infertility [3]. The maintenance of future 
fertility is considered of great importance by patients. At the time of cancer diagnosis, approximately half of 
the women are concerned about the potential loss of ovarian function and fertility due to use of cancer 
treatments [4]; moreover, fertility concerns can also influence their therapeutic decisions and the 
adherence to the suggested treatment [4, 5]. Cancer patients have a strong desire to have biological 
children instead of searching for other options such as adoption or egg donation [6]. Moreover, the 
development of secondary iatrogenic infertility negatively affects many aspects of their life and general 
well-being. For instance, lower marriage rates are found in these patients [7]. 
However, many patients do not choose to undergo fertility preservation procedures. This may be explained 
by the difficult moment they are facing, by the fact that they may not be aware of the potential fertility loss 
and by the fear of delaying cancer treatment [8]. It has been reported that adequate counseling improves 
the number of  women who choose to  undergo fertility preservation treatments [9]. Hence, as endorsed by 
major international guidelines, it is crucial to counsel all cancer patients in reproductive age about the 
treatment-related loss of fertility and to assist them in taking  decisions on fertility preservation [8, 10]. 
Oocytes cryopreservation is the preferred choice when embryo cryopreservation is not allowed or refused 
by the patients. Furthermore, preserving oocytes, and not embryos, gives the patient a reproductive 
autonomy: this is a relevant point taking into account the high risk of relationship disruption in female 
cancer survivors [11, 12]. 
The procedure of mature oocyte cryopreservation requires at least two weeks of controlled ovarian 
stimulation (COS) to induce multiple follicular growth and oocytes retrieval.  Since the success rate per 
oocyte is low [13, 14], it is crucial to obtain as many oocytes as possible [15].  
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COS can be considered safe in women with cancer when a 2-week delay in the initiation of cancer 
treatment is possible [3]. The safety of the procedure has been also demonstrated in women with 
hormone-sensitive cancers with the addition of letrozole or tamoxifen to the standard protocol for COS [16, 
17, 18].  
However, despite the endorsement of the major Oncology and Reproductive Medicine societies (Table 1), 
oocyte cryopreservation has not been widely adopted. As shown by Von Wolff and colleagues, this 
technique was chosen only by a minority of women in Germany, Austria and Switzerland between 2007 and 
2013 [9]. Several challenges, including a lack of knowledge of both patients and physicians on the topic, 
could explain such limited use of oocyte cryopreservation. This article aims at critically reviewing the 
available evidence about the success rates of oocyte cryopreservation in female cancer patients with the 
final goal to further improve the oncofertility counseling. 
 
Procedural challenges for cryopreserving the oocytes  
Mature oocytes (metaphase II, MII) are fragile cells and numerous challenges should be overcome for 
obtaining a successful cryopreservation procedure and subsequent storage. The oocyte is the largest 
human cell, with subsequent low surface area to volume ratio. The overall effect is that oocytes are likely to 
retain water during freezing and they are particularly vulnerable to physical injury by intracellular ice 
formation during the cryopreservation process. 
Moreover, addition or dilution of cryoprotective agents may further cause osmotic stress [23]. 
Cryopreservation can cause zona pellucida thickening, premature cortical granule exocytosis [24, 25], as 
well as risk of meiotic spindle disruption and aneuploidy [26, 27, 28, 29, 30]. In addition, animal [31, 32, 33, 
34] and human [35, 36, 37 ,38] studies have demonstrated that cryopreservation can also impact on gene 
expression profile of MII oocytes by deregulating genes related to oxidative stress, apoptosis, chromosomal 
structural maintenance, and cell cycle. The cryopreservation procedure seems to negatively affect 
proteomics. In fact, exposure of mouse oocytes to 1,2-propanediol cryoprotective agent showed to alter 
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the maternal proteins stored within the oocyte for fertilization support and early embryo development 
before the activation of the embryonic proteome [39, 40]. On one hand, a protein efflux due to disruption 
of the plasma membrane, possibly secondary to free-radical production, may explain a down-regulation of 
proteins following slow freezing. On the other hand, oocyte exposure to toxic cryoprotectants may 
determine up-regulation of stress proteins that can exhibit widely varied functions such as induction of 
apoptosis, impairment of meiotic division, and proteasome-mediated degradation. Overall, 
cryopreservation procedures may have negative effects on the physiology of the MII oocyte. It has been 
demonstrated that storage time in liquid nitrogen, if it is performed in a suitable way without any 
temperature alteration, does not alter the molecular integrity of the oocytes [38]. It follows that the 
potential damage produced to frozen/thawed oocytes is only due to the cryopreservation procedure per se 
rather than the storage-time. In support of this, prior clinical studies in controlled-rate cryopreserved and 
vitrified human oocytes [41, 42] demonstrated that long-term cryostorage does not adversely affect the 
outcome of oocyte thawing cycles. The discovery of no detrimental effects of storage time on the oocyte 
gene expression profile proves that the developmental potential of frozen/thawed oocytes is independent 
from the duration of their conservation in liquid nitrogen. The wider implication of this finding is 
noteworthy for the safety of long-term oocyte banking. This is of crucial importance for cancer patients, for 
whom several years after diagnosis may be required before trying to achieve a pregnancy with the use of 
the oocytes cryopreserved before starting treatment. 
 
Different methods for oocyte cryopreservation 
The available methods for oocyte cryopreservation are slow freezing (or controlled-rate cryopreservation) 
and vitrification [43]. In slow freezing cryopreservation, oocytes are slowly cooled to below the freezing 
point in the presence of low concentrations of cryoprotectant agents (e.g. sugars, propanediol). This allows 
to reduce intracellular ice formation and structural damage due to solute concentrations and osmotic stress 
[44, 45]. The term “vitrification” refers to any process resulting in “glass formation”, i.e. the transformation 
from a liquid to a solid in the absence of crystallization. For this purpose, oocytes are brought into a 
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medium that has a very high concentration of cryoprotective agents and then they are frozen at high 
cooling rates to become “vitrified” without forming ice crystals [46, 47, 48, 49]. 
The most used indicators of the efficacy of these procedures are ongoing pregnancy rate and live birth rate 
per embryo transfer. However, there is a large heterogeneity in the literature (i.e., not all studies reported 
live birth rate, sometimes results were reported per oocyte or per thawed cycle, etc) and different studies 
are not easily comparable. Table 2 summarizes the indicators for the evaluation of the success of fertility-
preserving procedure.  
A 2014 Cochrane review [50] evaluated the performance of slow freezing and vitrification in two 
randomized controlled trials (RCT) [51, 52]. One study was carried out in infertile women with 
supernumerary mature oocytes, while the other study was carried out with oocyte donors. Neither of the 
two RCTs analyzed the outcome in terms of live birth rate. As compared to slow freezing, vitrification was 
associated with an increased pregnancy rate (relative effect 3.86, 95% confidence intervals [CI] 1.63 to 
9.11, p= 0.002), oocyte survival rate after warming (80-90% vs. 45-67%) and fertilization rate (76-83% vs. 
54-68%). The main limitation of both studies was the small sample size. A large cohort study based on the 
Italian assisted reproductive technology (ART) registry evaluated the performance of oocyte 
cryopreservation in infertile patients with supernumerary mature oocytes. The study included 14,328 cycles 
performed from 2007 to 2011 in 146 centers. Vitrification was associated with a statistically significant 
higher performance in terms of pregnancy rate than slow-freezing (odds ratio [OR] = 1.23, 95% CI: 1.11-
1.35, P < 0.001), although results varied largely among the different centers. The pregnancy rate using the 
slow freezing technique was 12.0% for started thawing cycle and 14.8% considering only the cycles that led 
to an embryo transfer. Using vitrification the pregnancy rate increased to 14.4% and 18.0% respectively [53, 
54]. 
Of note, cryopreservation techniques are highly operator dependent, vitrification even more than slow-
freezing due to the need to complete the procedure within seconds [55]. While slow-cooling was the first 
technique to be used, in the last decade, vitrification has resulted in a breakthrough in oocyte 
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cryopreservation and has become the standard technique. A recent systematic review and meta-analysis 
including 6 RCT and 14 observational studies compared slow-freezing, vitrification, and the use of fresh 
oocytes. The meta-analysis suggested that vitrification/warming is superior to slow-freezing/thawing in 
terms of clinical outcome and cryosurvival rates. As for clinical outcome, the quality of evidence was 
considered low because only one RCT reported the clinical pregnancy rate as outcome. The difference 
between the two techniques was statistically significant only when comparing ongoing pregnancy rate per 
cycle of warming (RR = 2.81, 95% CI: 1.05–7.51; P = 0.039), but not ongoing pregnancy per transfer (RR = 
1.81, 95% CI: 0.71–4.67; P = 0.214). Vitrification seemed to have better oocyte survival rates than slow-
freezing: the meta-analysis of three RCT reported rates of 82.3% vs 66.1% (RR = 1.23, 95% CI: 1.02–1.49; P = 
0.031) [51, 56, 57, 58]. 
 
Efficacy and safety of oocyte cryopreservation 
The efficacy and safety of oocyte cryopreservation can be inferred from available data especially in two 
populations: infertile women and oocyte donors. 
During the first decades of use, overall success of both slow-cooling and vitrification techniques was low 
compared to in vitro fertilization (IVF) with unfrozen oocytes. In 2006 Oktay et al. reported a live birth rate 
per oocyte of 1.9% after slow freezing and 2.0% after vitrification [59]. Subsequently, four randomized 
controlled trials compared the efficacy of fresh vs. cryopreserved oocytes. Cobo et al. obtained similar 
success rates in recipients of fresh or vitrified donated oocytes [47, 60], and two Italian studies confirmed 
similar results using fresh and vitrified oocytes in infertile patients [48, 61]. Taking into account the results 
of these four RCT, in 2013 the American Society of Reproductive Medicine (ASRM) removed the 
“experimental” designation to oocyte cryopreservation [62].  
An year later, in 2014, a systematic review and meta-analysis of 17 studies reported an ongoing pregnancy 
rate per warmed oocyte of 7% (95% CI: 4-10%) [63], a significantly better result than the 2% reported by 
Oktay et al. in 2006 [59]. However, large multi-centric observational studies suggested that implantation 
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and pregnancy rates may be lower with frozen oocytes compared with fresh ones or frozen embryos [64, 
65]. 
Table 3 summarizes the results of the studies reporting the efficacy of oocyte cryopreservation in different 
settings (infertility, oocyte donation, elective cryopreservation, fertility preservation in cancer patients). 
Results reported by different centers showed that women’s characteristics affect the success of the 
procedure. In egg donation programs, with oocytes of young healthy women, the pregnancy rate was as 
high as 49.1% per embryo transfer [47]. In infertile patients, the results varie according to patients’ 
characteristics and the experience of the center. 
The Italian experience is particular in this context. From 2004 to 2009, the Italian law n. 40 banned the use 
of embryo cryopreservation, urging fertility centers to master oocytes cryopreservation techniques in 
infertile patients. A retrospective study examined the results from 24.173 cycles with frozen and then 
warmed oocytes reported in the ART national registry from 2005 to 2013. A total of 80.5% of the thawing 
cycles led to embryo transfer, but only 15.6% of the embryo transfers led to an ongoing pregnancy [54]. 
These findings were due to a possible selection bias (the best looking oocytes were used in fresh cycles) but 
also to differences in performance among centers. Centers with large experience had significantly better 
results, and, examining results per year, the ongoing pregnancy rate increased with the experience of the 
centre. 
From a safety perspective, thousands of babies have been born worldwide from frozen eggs, and several 
data are available on the obstetrics and neonatal outcomes of a great number of pregnancies. In 2009, 
Noyes et al. published a large retrospective study reporting the outcome of 900 babies born from oocytes 
cryopreserved with the slow freezing technique. This study reported an anomaly rate of 1.3%, not higher 
than the one expected in the general population [70]. In 2014, Cobo et al. reported the perinatal outcome 
of 1.027 children born from vitrified oocytes as similar to those obtained with fresh techniques [71]. The 
Italian ART registry reported a reassuring rate of congenital anomalies equal to 0.9% in 24.173 cycles from 
2004 to 2009 [53].  
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Efficacy of oocyte cryopreservation in cancer patients 
Although oocyte cryopreservation is routinely used as a method for fertility preservation, specific data on 
the success of the procedure in female cancer patients are limited so far. A first reason for this observation 
is that oocyte cryopreservation has been widely used from no more than 10 years. Second, after oocyte 
cryopreservation, women need time to treat their oncological disease before attempting to have a 
pregnancy. Third, not all the women who cryopreserved will decide to use their oocytes: some may not 
desire motherhood anymore and others may conceive spontaneously. Whereas it is known that only 10% 
of men who cryopreserved semen before oncological treatment come back to use it [72], the data on the 
utilization rate of cryopreserved oocytes are not yet available.  
The first live birth from frozen/thawed oocytes in a cancer patient was reported by Yang et al. in 2007 [73]. 
The patient was diagnosed with Hodgkin lymphoma at 27 years and decided to undergo oocyte 
cryopreservation using the slow-freezing technique. A total of 10 out of 13 MII cryopreserved oocytes 
(77%) survived after thawing. Three embryo transfers were performed on a gestational carrier and the third 
one resulted in a single ongoing pregnancy and live birth at term. Since then, few more live births have 
been reported in the literature mainly as single case reports (Table 4). Two small retrospective studies 
reported data on the outcomes of cancer patients who underwent oocyte cryopreservation before cancer 
treatments. Martinez et al. [68], described the outcome of 11 patients. The ongoing pregnancy rate per 
embryo transfer was 54,5% and 4 patients delivered 5 healthy newborns at term. At the time of the 
cryopreservation procedure, median age was 35.6 years and the number of cryopreserved MII oocytes 
ranged from 3 to 10. Of these four patients, three had infiltrating ductal breast carcinoma treated with 
surgery and chemotherapy (plus tamoxifen in two of three cases) and the fourth had non-Hodgkin 
lymphoma. This last patient did not receive chemotherapy after oocytes cryopreservation but underwent 
an intracytoplasmic sperm injection (ICSI) cycle with the cryopreserved oocytes because of a severe male 
factor. Of note, the oldest patient of this cohort (41 years old) cryopreserved 10 oocytes but obtained no 
euploid embryos after fertilization and did not undergo embryo transfer. In 2016 Druckenmiller et al. [69] 
reported a 44% live birth rate per embryo transfer after thawing/warming of oocytes in 10 patients with a 
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median age of 32 years. Oocyte survival rate and fertilization rate were similar to the ones obtained in 
patients without cancer at the same institution (live birth rate of 33% in non-cancer patients of less than 43 
years). A relatively large number of oocytes (n=7, interquartile range: 6-13) was thawed to guarantee 
fertilizing in at least two of them.  
Five newborns were delivered (3 singleton pregnancies and one twin pregnancy). Three women were 
breast cancer patients and the fourth had a gynecologic malignancy. In one of the three breast cancer 
patients, a gestational carrier was used because post treatment pregnancy was not recommended.  
The limited available data in cancer patients do not allow to draw significant conclusions about the 
outcome of oocyte cryopreservation in this setting; hence, the efficacy and safety of the procedure is 
inferred from the results in the general population. Of note, the oocytes obtained from cancer patients 
usually remain frozen for a longer period of time as compared with infertile non-oncologic women. This 
could be another confounding factor to assess the efficacy of the procedure in the oncologic population, 
even though recent evidence suggested that storage time does not affect the cryopreserved MII oocytes at 
the gene expression level, if the procedure of cryopreservation is adequately performed [38]. However, as 
mentioned above, the efficacy of oocyte cryopreservation increases with the number of cryopreserved 
gametes. Therefore it is important to define if there is a reduced ovarian response to stimulation in cancer 
patients.  
Ovarian response to stimulation in cancer patients  
The effect of cancer on patients’ ovarian reserve and consequently on the response to COS is a key factor 
for the success of oocyte cryopreservation.  
In 2012, a systematic review and meta-analysis performed by Friedler et al. [80] compared the outcomes of 
227 COS cycles in female cancer patients with those of 1258 cycles in infertile patients. The study showed 
that less oocytes were retrieved in patients with cancer as compared to the infertile non oncologic 
population (11.7 + 7.5 vs.13.5 +8.4, P < 0.002). However the studies considered were not homogeneous, 
and the dose of gonadotropines used for COS varied significantly between cases and controls. Subsequent 
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studies [81, 82] did not confirm this result. A recent retrospective cohort study [83] matched 244 women 
with a recent cancer diagnosis and no history of infertility with 362 non-oncologic women undergoing COS 
for elective fertility preservation. Cancer diagnosis was not associated with a decreased ovarian reserve, 
response to COS and number of retrieved oocytes. Another recent study by the same group demonstrated 
also that the inclusion of letrozole in the protocol for controlled ovarian stimulation did not seem to be 
associated with a negative impact on cycle outcome or oocyte maturity [84]. 
The study by Druckenmiller et al. [69] analyzed also the difference in ovarian response to COS according to 
the type of cancer. Patients with hematologic malignancies had the highest number of cryopreserved 
oocytes, whereas patients with breast malignancies had the lowest. Ovarian cancer patients cryopreserved 
a low number of oocytes, probably due to a direct insult of the cancer or the required surgery to the 
ovarian function. Conversely, uterine cancer patients obtained a high number of oocytes; this was probably 
a consequence of an underlying polycystic ovarian syndrome.  
Overall, the available data shows no significant difference in ovarian response in cancer and non-cancer 
patients. A possible reduced response to COS may occur in BRCA mutated cancer patients, even if available 
data in this subgroup of women are limited and still controversial to draw solid conclusions [85, 86]. 
If we consider valid the hypothesis that the cancer per se does not reduce the response to COS and the 
quality of the oocytes, the results in infertile women and oocyte donors can then be generalized to inform 
patients during the oncofertility counseling about efficacy and safety of the procedure. In this scenario, the 
main predictive factors for the overall success of the procedure are the expertise of the laboratory (the 
efficiency of the cryopreservation technique and the learning curve of the operators) and the individual 
characteristics of the women at the time of the procedure (age, ovarian reserve). 
 
Finding the ideal candidate for oocyte cryopreservation 
During oncofertility counseling, when discussing the efficacy of the available methods for fertility 
preservation, the ability to estimate the success of the proposed technique is essential. Anti-Mullerian 
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hormone (AMH) and antral follicle count (AFC) are widespread used markers of ovarian reserve in the 
general population and can be used as predictors of response to COS in ART procedures, also in cancer 
patients [87]. In the study by Lee et al. including 41 women with breast cancer that underwent ovarian 
stimulation (with the addition of letrozole) for embryo/oocyte cryopreservation, AMH and AFC were 
predictive of the ovarian response [88]. Specifically, AMH was the most reliable marker, with a likelihood of 
low response for values inferior to 1.2 ng/ml. 
Besides the markers of ovarian reserve, age remains the strongest determinant of the success of the 
technique. In a recent study, Doyle et al. [67] analyzed 128 autologous IVF cycles from a total of 1283 
vitrified oocytes of infertile non-oncologic women who underwent cryopreservation both electively or for 
medical reasons. Age was the most reliable predictor of the oocyte-to-live-birth efficiency in this cohort. 
The age-associated live birth rate per warmed oocyte ranged from 8.7% in women aged <30 years to 1.1% 
in women aged 43–44 years, with an overall oocyte to child efficiency of 6.7%. Cryopreservation of 15-20 
MII oocytes gave women aged <38 years a 70-80% chance of at least one live birth, while for women aged 
38-40 the number of MII oocytes needed to give a 65-70% chance of a live birth increased to 25-30.  To 
obtain more oocytes, it has been proposed to perform two ovarian stimulation, one immediately after the 
other [89]. However, in cancer patients the double stimulation is not always feasible, due to the need to 
start anticancer therapies. Moreover, in older patients, the probability of having a high number of MII 
oocytes is low even when a double stimulation is performed. 
The FertiPROTEKT network registry, including data from Germany, Austria and Switzerland [9] reported a 
mean of 12.1 + 9.9 cryopreserved oocytes in women with cancer younger than 30 years. The numbers 
decreased to 8.7 + 7.1 in women aged 36-40, and to only 5.0 + 8.7 in women over 40 years of age.  
These numbers are significantly lower than those indicated by Doyle et al. [67] to guarantee a good chance 
of live birth. However, the main target of the article by Doyle and colleagues was the evaluation of the cost-
effectiveness of cryopreservation for non-medical reason (i.e., social freezing). In order to be cost-effective 
(both in terms of economic costs and procedure-associated risks), an elective procedure should guarantee a 
success rate higher than the one expected spontaneously in the same population. If we consider oocyte 
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cryopreservation in cancer patients, the setting is completely different from elective oocyte preservation. 
Fertility in these patients will be affected not only by the advancing age, but also by the gonadotoxic effect 
of therapies; hence, for their future fertility, many cancer patients will have to relay mainly on 
cryopreserved oocytes. 
 
Counseling in difficult cases: old and very young women 
Since the risk of cancer treatment-related infertility increases with age, women with the highest probability 
of developing permanent amenorrhea are often also the ones in which fertility preservation treatments 
have the lowest chances of success. In facing these situations, a proper oncofertility counseling by fertility 
specialists is crucial. Hence, a personalized counseling to provide all the information regarding risks, 
benefits and success rates is mandatory before subjecting a patient to a known inefficient treatment. 
Alternatives like egg donation or adoption should be discussed as well, specifically with patients with 
predictably low chances of success with oocyte cryopreservation. It is not always clear when and where to 
draw the line to consider feasible the fertility preservation procedure. As discussed above, age is the most 
reliable predictor; however, there is no agreement on the age limit for offering  a cryopreservation 
technique. Druckenmiller et al. [69] proposed to offer oocyte cryopreservation before the age of 43, based 
on the data of their center showing a 36% live births in non-oncologic infertile women aged 41-42 years. On 
the contrary, Doyle et al. [67] reported that the success of the procedure in women over the age of 40 is 
unlikely. In this setting, age together with markers of ovarian reserve and centre's experience (i.e., success 
rate in non-cancer patients) should be considered as useful tools to make an informed and shared decision 
with the patient. In general, it can be stated that oocyte cryopreservation over the age of 40 years should 
be considered exceptional. 
Children and adolescent undergoing gonadotoxic therapies are also difficult to counsel. Prepubertal girls 
who do not yet ovulate due to an immature hypotalamic-pituitary axis are not candidates to COS and 
subsequent oocyte cryopreservation. A feasible alternative for these patients is ovarian tissue 
  14 
cryopreservation with or without in vitro maturation of immature oocytes [90]. COS and oocyte 
cryopreservation are effective options in post-pubertal girls [91]. However, pediatric cancers are frequently 
more aggressive and sometimes a 2-week delay in treatment is not possible [92]. Moreover, younger girls 
may find emotionally difficult being subjected to serial transvaginal ultrasounds and transvaginal oocyte 
retrieval. Both young patients and parents need accurate education and counseling about the safety and 
effectiveness of the procedure. During the process of informed consent acquisition, adolescents should be 
treated as subjects with increasing autonomy, both legally and because of their physical and mental level of 
development [93].  
Conclusions 
Physicians should offer fertility preservation to women facing gonadotoxic therapies, with an adequate 
counseling within a multidisciplinary contest that includes a fertility specialist. During oncofertility 
counseling, all the options, both standard and experimental ones, should be presented with an estimate of 
their efficacy and safety adjusted on the characteristics and needs of the patient, including a discussion on 
the possibility of delaying treatment initiation. 
Oocyte cryopreservation is a standard fertility preserving procedure that allows to conserve reproductive 
autonomy. It can be considered an effective and safe method to preserve fertility to be done in centers 
with the adequate expertise given the technical difficulty of the laboratory phase. Cancer patients should 
be aware that, despite the paucity of data on pregnancies from cryopreserved oocytes in the oncologic 
population, the reassuring efficacy and safety resulting from infertile non-oncologic patients can be 
reasonably translated to them. The informed consent to access the procedure should include an estimate 
of the chance of success based on both patient’s characteristics (age, ovarian reserve) and the statistics of 
the center. The possibility that no oocytes may survive after thawing/warming should be also discussed. 
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